This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta

BOSTON ( TheStreet) -- The Biotech Stock Mailbag is back after a two-week hiatus. I wrote long this week, so grab a cup of Friday coffee and dig in. The prize for making it to the end of the Mailbag is some hellaciously good hate email and tweets.

To select the next test cases for the Feuerstein-Ratain Rule, I ran a screen using BioMedTracker for companies with cancer drugs in phase III studies expected to announce top-line results within the next six months.

Remember, the F-R Rule tries to predict the outcome of phase III studies of cancer drugs based on the market cap of the company conducting the study four months prior to the expected results.

Here's what I came up with:

Oncogenex Pharmaceuticals (OGXI): The "Synergy" study of custirsen in combination with docetaxel in first-line prostate cancer patients should have survival results ready in mid-2014. That timeline makes Oncogenex a bit early for assessment by the F-R Rule but keep it in mind.

Merrimack Pharmaceuticals (MACK): The "Napoli 1" study of MM-398 in pancreatic cancer should have top-line results in the fourth quarter or first quarter next year. I put MM-398 through the F-R Rule buzzsaw in a previous Mailbag.

Onconova Therapeutics (ONTX - Get Report): The "OnTime" study of Estybon (rigosertib) in high-risk myelodysplastic syndrome will have results ready in the fourth quarter or first quarter 2014.

Cyclacel Pharmaceuticals (CYCC): An interim analysis of the sapacitabine "Seamless" study in acute myelogenous leukemia may take place in the first quarter 2014.

NewLink Genetics (NLNK): Timing is a bit fuzzy here but we could get data (interim? final?) from the "Impress" study of HyperAcute Pancreas in pancreatic cancer within the first six months of 2014.

A description of the Feuerstein-Ratain Rule can be found here. One note: Given the biotech bull market/bubble, particularly in small-cap stocks, the $300 million "dead zone" threshold -- 0% chance of study success -- probably needs to be expanded. By how much, I'm not sure. $400 million market cap? Does that sound right?

Okay, let's do the math. It's tough to nail down a narrow time frame for the rigosertib results but I'm going to use Jan. 1, 2014 since guidance from Onconova is fourth quarter 2013-first quarter 2014.

Four months back from Jan. 1, 2014 is Sept. 1, 2013, which puts Onconova's market cap at $520 million. That's nicely outside the historic F-R dead zone, which is encouraging for rigosertib's chances in the MDS trial.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARIA $8.27 4.68%
CPRX $4.13 5.63%
ONTX $2.37 0.00%
SRPT $30.43 7.98%
VNDA $12.69 2.34%

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.12 +5.48 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs